

102.174

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

M. Dibrino

LE GAL et al

Serial No.: 09/673,166

Group: 1644

Filed: October 6, 2000

For: LIPOPEPTIDE...VACCINATION

475 Park Avenue South New York, N.Y. 10016 April 30, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Serv

Sir:

Responsive to the office action of April 21, 2004, reconsideration of this application is requested in view of the remarks presented herein.

The claims in the application are claims 23 to 42, all other claims having been cancelled.

The office action indicated that the response of January 6, 2004 was not fully responsive since Applicants elected the HIV NEF 68-82 multi-epitope peptide but the Examiner was of the opinion that no such peptide was disclosed consisting of amino acid residue 68-82 and required Applicants to elect a single disclosed peptide with a specific ID number.

Applicants respectfully believe that the Examiner has misinterpreted the invention. Applicants elected the multi-epitope peptide HIV NEF 68-82 as the CTL epitope. Such a lipopeptide is named TT-NEF at the bottom of Table 8 of the specification and has the following amino acid sequence FPVTP QBPLRPMTYK and this can easily seen from the various peptides derived from the NEF protein including 68-76 and 73-82 peptides. Moreover, the elected lipopeptide consists of the lipopeptide of SEQ ID No: 276 of the sequence listing as disclosed on page 66 of the sequence listing. Therefore, it is believed that Applicants were clearly responsive to the office action of November 7, 2003.

Applicants look forward to obtaining the next office action

Respectfully submitted, Muserlian, Lucas and Mercanti

Charles A. Muserlian, 19,683

Attorney for Applicants

Tel. # (212) 661-8000

CAM:ds Enclosure

2